2024年7月8日 · Kriya is targeting diseases that impact millions of people worldwide and represent areas of high unmet need. We target validated biological pathways with innovative gene therapy approaches that have the potential to deliver transformative benefits.

2024年1月5日 · Kriya is developing KRIYA-586, a one-time, adeno-associated virus (AAV) gene therapy that drives durable expression of a monoclonal antibody that blocks IGF-1 receptors.

Britt Petty is Chief Manufacturing Officer at Kriya. He joined Kriya from AveXis, a Novartis company, focused on the development and commercialization of gene therapies for neurological genetic diseases, where he was the Chief Technical Officer (interim) and Head of …

Kriya’s KRIYA-839, an adeno-associated virus (AAV)-based gene therapy, is a groundbreaking approach to restoring insulin production and enhancing glucose metabolism in type 1 diabetes. Skeletal muscle plays a key role in regulating blood glucose in response to insulin.

2021年7月14日 · Kriya is built on two distinct technology platforms: its computationally enabled proprietary platform for rational vector design (SIRVE™) and its innovative high-efficiency manufacturing platform for scalable and low-cost production (STRIPE™).

Kriya is developing a portfolio of one-time gene therapies to address common diseases. Our current pipeline includes three main therapeutic areas: Therapeutic Area

2022年5月16日 · Kriya’s product pipeline addresses diseases of high unmet need with therapeutic area divisions in ophthalmology, oncology, rare disease, and chronic disease, each led by industry veterans with a track record of advancing products from concept through commercialization.

Kriya’s adeno-associated virus (AAV) gene therapy is designed to durably express an engineered ion channel focally within the trigeminal nerve, which may provide targeted pain relief.

2023年7月26日 · With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $600 million in committed capital, which will be used to advance a broad pipeline of gene therapies for ophthalmology, neurology and metabolic disease.

Kriya shares the latest news on our pipeline of life-changing gene therapies to address common diseases.